Gastrointestinal stromal tumors: CT and MRI findings K Sandrasegaran, A Rajesh, DA Rushing, J Rydberg, FM Akisik, ... European radiology 15, 1407-1414, 2005 | 354 | 2005 |
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients … GD Demetri, SP Chawla, I Ray-Coquard, A Le Cesne, AP Staddon, ... Journal of Clinical Oncology 31 (19), 2485-2492, 2013 | 269 | 2013 |
Doxorubicin clearance in the obese. KA Rodvold, DA Rushing, DA Tewksbury Journal of Clinical Oncology 6 (8), 1321-1327, 1988 | 247 | 1988 |
Gastrointestinal stromal tumors: clinical, radiologic, and pathologic features K Sandrasegaran, A Rajesh, J Rydberg, DA Rushing, FM Akisik, ... American Journal of Roentgenology 184 (3), 803-811, 2005 | 214 | 2005 |
Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma LE Davis, V Bolejack, CW Ryan, KN Ganjoo, ET Loggers, S Chawla, ... Journal of Clinical Oncology 37 (16), 1424-1431, 2019 | 211 | 2019 |
Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer SC Piscitelli, KA Rodvold, DA Rushing, DA Tewksbury Clinical Pharmacology & Therapeutics 53 (5), 555-561, 1993 | 151 | 1993 |
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor SM Schuetze, V Bolejack, E Choy, KN Ganjoo, AP Staddon, WA Chow, ... Cancer 123 (1), 90-97, 2017 | 120 | 2017 |
SARC009: phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma SM Schuetze, JK Wathen, DR Lucas, E Choy, BL Samuels, AP Staddon, ... Cancer 122 (6), 868-874, 2016 | 102 | 2016 |
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers M Radovich, PJ Kiel, SM Nance, EE Niland, ME Parsley, ME Ferguson, ... Oncotarget 7 (35), 56491, 2016 | 98 | 2016 |
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. HI Robins, D Rushing, M Kutz, KD Tutsch, CL Tiggelaar, D Paul, ... Journal of clinical oncology 15 (1), 158-164, 1997 | 97 | 1997 |
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). JC Trent, K Wathen, M Von Mehren, BL Samuels, AP Staddon, E Choy, ... Journal of Clinical Oncology 29 (15_suppl), 10006-10006, 2011 | 91 | 2011 |
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma KN Ganjoo, LD Cranmer, JE Butrynski, D Rushing, D Adkins, SH Okuno, ... Oncology 80 (1-2), 50-56, 2011 | 90 | 2011 |
The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer DA Rushing, SR Raber, KA Rodvold, SC Piscitelli, GS Plank, ... Cancer 74 (3), 834-841, 1994 | 89 | 1994 |
SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy‐naive malignant peripheral nerve sheath tumors CS Higham, SM Steinberg, E Dombi, A Perry, LJ Helman, SM Schuetze, ... Sarcoma 2017 (1), 8685638, 2017 | 87 | 2017 |
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy S Patel, ML Keohan, MW Saif, D Rushing, L Baez, K Feit, R DeJager, ... Cancer 107 (12), 2881-2887, 2006 | 82 | 2006 |
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a … ML Hensley, SR Patel, M von Mehren, K Ganjoo, RL Jones, A Staddon, ... Gynecologic oncology 146 (3), 531-537, 2017 | 69 | 2017 |
Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or … S Patel, M von Mehren, DR Reed, P Kaiser, J Charlson, CW Ryan, ... Cancer 125 (15), 2610-2620, 2019 | 61 | 2019 |
Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia D Rushing, A Goldman, G Gibbs, R Howe, BJ Kennedy American journal of clinical oncology 5 (3), 307-314, 1982 | 53 | 1982 |
Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel E McCartney, S Valluri, D Rushing, R Burgett Ophthalmic Plastic & Reconstructive Surgery 23 (2), 170-171, 2007 | 48 | 2007 |
A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. S Attia, V Bolejack, KN Ganjoo, S George, M Agulnik, DA Rushing, ... Journal of Clinical Oncology 35 (15_suppl), 11005-11005, 2017 | 39 | 2017 |